Akorn-Strides, is a joint venture that was formed in 2005 by Akorn and Strides Arcolab.
Arthur Przybyl, president and CEO of Akorn and member manager of Akorn-Strides, said: “The joint venture has now placed purchase orders for five injectable abbreviated new drug application (ANDA) products, one for fosphenytoin sodium, two for ondansetron, one for flumazenil and one for an expected ANDA approval in the near term. The joint venture expects to launch these products in 2008.”